Baloxavir Marboxil

Brand names: Xofluza · Active ingredient: Baloxavir Marboxil

In short: XOFLUZA is indicated for treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications 1 . XOFLUZA is indicated for post-exposure prophyla

Forms & strengthsXOFLUZA Tablets: 80 mg: white to light yellow, oblong shaped, film-coated, debossed with "BXM80" on one side.
LabelSportpharm LLC
Label updatedApr 27, 2026

What is Baloxavir Marboxil used for?

XOFLUZA is indicated for treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications

1

.

XOFLUZA is indicated for post-exposure prophylaxis of influenza in persons 5 years of age and older following contact with an individual who has influenza

.

Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA

.

Baloxavir Marboxil dosage

XOFLUZA is available in two dosage forms:

XOFLUZA tablets (40 mg and 80 mg).

XOFLUZA for oral suspension is available in two different presentations: packets (30 mg and 40 mg) and bottles (2 mg/mL). If the patient weighs less than 15 kg, XOFLUZA for oral suspension in bottle is the recommended presentation. Both presentations of the for oral suspension are intended for patients who are unable to or have difficulty swallowing tablets, or those who require enteral administration

.

Take XOFLUZA as soon as possible after influenza symptom onset or exposure to influenza

.

XOFLUZA may be taken with or without food. However, concomitant use of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc) should be avoided

.

Treatment of Acute Uncomplicated Influenza or Post-Exposure Prophylaxis in Adults, and Pediatric Patients (5 Years of Age and Older)

Take XOFLUZA as a single dose as soon as possible and within 48 hours of influenza symptom onset for treatment of acute uncomplicated influenza or following contact with an individual who has influenza. The recommended dosage of XOFLUZA in patients 5 years of age or older is a single weight-based dose displayed in

Tables 1,

2and

3.

Patient Body Weight | Recommended Single Oral Dose (Tablets)

Recommended XOFLUZA dosage is based on the patient's weight.

20 kg to less than 80 kg | One 40 mg tablet

(blister card contains one 40 mg tablet)

At least 80 kg | One 80 mg tablet

(blister card contains one 80 mg tablet)

Patient Body Weight | Recommended Single Oral Dose (Packets)

Recommended XOFLUZA dosage is based on the patient's weight.

15 kg

Patients who weigh less than 15 kg should receive XOFLUZA for oral suspension (bottles).to less than 20 kg | One 30 mg packet

20 kg to less than 80 kg | One 40 mg packet

At least 80 kg | 80 mg (two 40 mg packets)

Patient Body Weight | Recommended Single Oral Dose

Recommended XOFLUZA dosage is based on the patient's weight.

,

Use a measuring device (oral syringe) to measure the prescribed dose for use.(For Oral Suspension in Bottles)

Less than 20 kg | 2 mg/kg

20 kg to less than 80 kg | 40 mg (20 mL)

At least 80 kg | 80 mg (40 mL

Dosage requires two bottles of XOFLUZA for oral suspension.)

See the XOFLUZA for oral suspension (packets) Instructions for Use for details on the preparation and administration (oral or via enteral feeding tube).

For the 30 mg or 40 mg dose, mix in a small container with 1 tablespoon (about 15-20 mL) of room temperature drinking water. Once the supplied XOFLUZA for oral suspension (packets) have fully dispersed in the drinking water, take the entire mixture immediately.

For the 80 mg dose, use two 40 mg packets. …

How to take Baloxavir Marboxil — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Important Dosing Information

Instruct patients to begin treatment with XOFLUZA as soon as possible at the first appearance of influenza symptoms, within 48 hours of onset of symptoms. Instruct patients to start taking XOFLUZA for prevention as soon as possible after exposure

.

XOFLUZA can be taken with or without food, but advise patients not to take with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc)

.

Advise patients to follow the healthcare provider's dosing recommendation for a single, one-time dose of XOFLUZA. XOFLUZA is dosed based on weight and is available as tablets, and for oral suspension (packets and bottles). XOFLUZA for oral suspension in a packet is not made into a suspension but rather mixed with a small amount of room temperature drinking water to aid administration.

Tablets: Provided as a blister card containing either one tablet of 40 mg, or one tablet of 80 mg as a single dose

. …

Warnings & precautions

Do not take this medicine if: XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme

.

Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected. The use of XOFLUZA is contraindicated in patients with known hypersensitivity to XOFLUZA

.

XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group. In clinical trials, the incidence of virus with treatment-emergent substitutions associated with reduced susceptibility to baloxavir (resistance) was higher in pediatric subjects younger than 5 years of age (40%, 38/96) than in pediatric subjects ≥ 5 years to < 12 years of age (16%, 19/117) or subjects ≥ 12 years of age (7%, 60/842). The potential for transmission of resistant strains in the community has not been determined

[see

Indications and Usage (1),

Use in Specific Populations (8.4), and

Microbiology (12.4)].

There is no evidence of efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Baloxavir Marboxil side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The overall safety profile of XOFLUZA is based on data from 2,079 subjects, 5 years of age and older in 5 controlled clinical trials who received XOFLUZA. Of these subjects, 1,943 were adults and adolescents (≥ 12 years of age) and 136 were in the pediatric age group (5 to < 12 years of age)

.

Treatment of Acute Uncomplicated Influenza

Adult and Adolescent Subjects (≥ 12 Years of Age):

The safety of XOFLUZA in adult and adolescent subjects is based on data from 3 placebo-controlled trials in which a total of 1,640 subjects received XOFLUZA: 1,334 (81%) subjects were 18 to 64 years of age, 209 (13%) subjects were adults 65 years of age or older, and 97 (6%) subjects were adolescents 12 to 17 years of age. These trials included otherwise healthy adults and adolescents (N=910) and subjects at high risk of developing complications associated with influenza (N=730). Of these, 1,440 subjects received XOFLUZA at the recommended dose

.

Trial T0821 was a phase 2 dose-finding placebo-controlled trial where otherwise healthy adult subjects 20 to 64 years of age received single oral dose of XOFLUZA or placebo. …

Drug interactions

Baloxavir may form a chelate with polyvalent cations such as calcium, aluminum, or magnesium. Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir

,

which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and thereby decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

About this medicine

Baloxavir marboxil is an influenza virus PA endonuclease inhibitor.

The active component of XOFLUZA is baloxavir marboxil. The chemical name of baloxavir marboxil is ({(12aR)-12-[(11S)-7,8-Difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl}oxy)methyl methyl carbonate. The empirical formula of baloxavir marboxil is C

27H

23F

2N

3O

7S, and the chemical structure is shown below.

Baloxavir marboxil has a molecular mass of 571.55 grams per mole and a partition coefficient (log P) of 2.26. It is freely soluble in dimethylsulfoxide, soluble in acetonitrile, slightly soluble in methanol and ethanol, and practically insoluble in water.

XOFLUZA is supplied as tablets.

XOFLUZA tablets are white to light yellow, film-coated for oral administration

.The 80 mg film-coated tablet contains 80 mg of baloxavir marboxil. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b58b2899-4d22-41e1-8f0c-bdead8917694. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin